OraSure Technologies, Inc. has entered wide-ranging strategic distribution agreements with Sapphiros and certain of its related entities. The company has since developed innovative capabilities including novel sample collection, next-generation detection systems, computational biology, and printed electronics to help consumers access diagnostic results. Through this strategic relationship, OraSure expects to be able to offer a more comprehensive range of low-cost diagnostic tests and sample management solutions to its customers globally.

OraSure has secured exclusive distribution rights to key products in Sapphiros? development pipeline that align with and enhance OraSure?s existing areas of expertise, including self-collected blood samples and diagnostic tests for sexually transmitted infections, respiratory conditions, and other diseases. This partnership connects Sapphiros?

innovation and robust product pipeline with OraSure?s strength in commercial distribution to serve new and existing market segments. It also creates opportunities for further collaboration in co-developing future products and advancing Sapphiros? novel platforms for next-generation lateral flow devices, break-through molecular technologies, and advanced biosensors.

Initial product distribution is expected to begin in 2024, with multiple additional products expected to launch in 2025 and beyond, subject to regulatory approvals. Distribution of Sapphiros? products is expected to accelerate revenue growth in OraSure?s core business beginning in 2025.